Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013

J. Bradley Layton, Yoonsang Kim, G. Caleb Alexander, Sherry L. Emery

Research output: Contribution to journalArticle

Abstract

IMPORTANCE Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time. OBJECTIVE To investigate associations between televised DTCA and testosterone testing and initiation in the United States. DESIGN, SETTING, AND POPULATION Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations. EXPOSURES Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs. MAIN OUTCOMES AND MEASURES (1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing. RESULTS Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95%CI, 1.004-1.008), initiation (RR, 1.007; 95%CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95%CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95%CI, 0.09-0.19), 0.05 new initiations (95%CI, 0.03-0.08), and 0.02 initiations without a recent test (95%CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period. CONCLUSIONS AND RELEVANCE Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.

Original languageEnglish (US)
Pages (from-to)1159-1166
Number of pages8
JournalJAMA - Journal of the American Medical Association
Volume317
Issue number11
DOIs
StatePublished - Mar 21 2017

Fingerprint

Testosterone
Serum
Southeastern United States
Insurance
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. / Layton, J. Bradley; Kim, Yoonsang; Alexander, G. Caleb; Emery, Sherry L.

In: JAMA - Journal of the American Medical Association, Vol. 317, No. 11, 21.03.2017, p. 1159-1166.

Research output: Contribution to journalArticle

Layton, J. Bradley; Kim, Yoonsang; Alexander, G. Caleb; Emery, Sherry L. / Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013.

In: JAMA - Journal of the American Medical Association, Vol. 317, No. 11, 21.03.2017, p. 1159-1166.

Research output: Contribution to journalArticle

@article{dce4e41e24ce4521adad337027e41751,
title = "Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013",
abstract = "IMPORTANCE Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time. OBJECTIVE To investigate associations between televised DTCA and testosterone testing and initiation in the United States. DESIGN, SETTING, AND POPULATION Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations. EXPOSURES Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs. MAIN OUTCOMES AND MEASURES (1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing. RESULTS Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95%CI, 1.004-1.008), initiation (RR, 1.007; 95%CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95%CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95%CI, 0.09-0.19), 0.05 new initiations (95%CI, 0.03-0.08), and 0.02 initiations without a recent test (95%CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period. CONCLUSIONS AND RELEVANCE Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.",
author = "Layton, {J. Bradley} and Yoonsang Kim and Alexander, {G. Caleb} and Emery, {Sherry L.}",
year = "2017",
month = "3",
doi = "10.1001/jama.2016.21041",
volume = "317",
pages = "1159--1166",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013

AU - Layton,J. Bradley

AU - Kim,Yoonsang

AU - Alexander,G. Caleb

AU - Emery,Sherry L.

PY - 2017/3/21

Y1 - 2017/3/21

N2 - IMPORTANCE Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time. OBJECTIVE To investigate associations between televised DTCA and testosterone testing and initiation in the United States. DESIGN, SETTING, AND POPULATION Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations. EXPOSURES Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs. MAIN OUTCOMES AND MEASURES (1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing. RESULTS Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95%CI, 1.004-1.008), initiation (RR, 1.007; 95%CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95%CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95%CI, 0.09-0.19), 0.05 new initiations (95%CI, 0.03-0.08), and 0.02 initiations without a recent test (95%CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period. CONCLUSIONS AND RELEVANCE Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.

AB - IMPORTANCE Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time. OBJECTIVE To investigate associations between televised DTCA and testosterone testing and initiation in the United States. DESIGN, SETTING, AND POPULATION Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations. EXPOSURES Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs. MAIN OUTCOMES AND MEASURES (1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing. RESULTS Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95%CI, 1.004-1.008), initiation (RR, 1.007; 95%CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95%CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95%CI, 0.09-0.19), 0.05 new initiations (95%CI, 0.03-0.08), and 0.02 initiations without a recent test (95%CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period. CONCLUSIONS AND RELEVANCE Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.

UR - http://www.scopus.com/inward/record.url?scp=85016102141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016102141&partnerID=8YFLogxK

U2 - 10.1001/jama.2016.21041

DO - 10.1001/jama.2016.21041

M3 - Article

VL - 317

SP - 1159

EP - 1166

JO - JAMA - Journal of the American Medical Association

T2 - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 11

ER -